BIPIX Performance — Biotechnology UltraSector ProFund, Investor Class
Data updated: 2026-10-13
BIPIX returned +27.55% year to date and +112.99% over one year to Jul 2026. Annualised returns are +23.74% over 3 years and +10.58% over 5 years. The fund beat its Trading - Leveraged category average: $100 invested three years ago grew to $189, against $136 for the category, and to $213 over one year, against $105. Volatility over the past three years was 39.30% a year. In the 12 months to Jul 2026 the fund lost a net $16.9M, and assets reached $118.70M.
BIPIX Growth of $100
What $100 invested in Biotechnology UltraSector ProFund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | BIPIX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $213 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $189 | $136 |
| 5 years (Aug 2021 – Jul 2026) | $165 | $130 |
| Since data start (Aug 2019 – Jul 2026) | $314 | $147 |
BIPIX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +27.55% |
| 1 year | +112.99% |
| 3 years (annualised) | +23.74% |
| 5 years (annualised) | +10.58% |
BIPIX Annual Returns
Calendar-year total returns of Biotechnology UltraSector ProFund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +27.55% |
| 2025 | +48.00% |
| 2024 | −5.21% |
| 2023 | +10.11% |
| 2022 | −13.43% |
| 2021 | +23.82% |
| 2020 | +20.09% |
| 2019 (Aug–Dec) | +23.64% |
BIPIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.9% | +2.7% | −0.4% | +3.9% | +5.8% | +23.7% | −10.9% | — | — | — | — | — |
| 2025 | +3.8% | −6.8% | −13.2% | +2.3% | −7.5% | +6.7% | +4.5% | +7.0% | +17.2% | +19.0% | +13.5% | −1.4% |
| 2024 | −3.6% | +18.4% | −5.5% | −16.6% | +7.4% | +5.8% | +9.8% | +2.9% | −4.0% | −3.2% | +3.4% | −14.6% |
| 2023 | +0.4% | −6.5% | −3.0% | +7.6% | +6.9% | −2.0% | +1.4% | −9.1% | −11.6% | −14.4% | +20.6% | +27.6% |
| 2022 | −14.0% | −3.6% | +8.2% | −14.0% | +2.4% | −2.7% | +6.0% | −8.6% | −4.5% | +13.9% | +12.0% | −4.6% |
| 2021 | +8.1% | −2.7% | −0.9% | +6.5% | −0.4% | +9.5% | +5.4% | +6.5% | −10.5% | −0.1% | −3.0% | +4.9% |
| 2020 | −9.4% | +0.9% | −6.2% | +20.1% | +10.7% | +1.8% | +0.1% | −1.4% | −3.3% | −9.3% | +16.6% | +2.5% |
| 2019 | — | — | — | — | — | — | — | −1.5% | −0.2% | +10.0% | +13.5% | +0.7% |
BIPIX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 39.30%
- 3-year Sharpe ratio: 0.49 (vs 4.5% risk-free rate)
- Best month: +27.64% (Dec 2023)
- Worst month: −16.64% (Apr 2024)
BIPIX Fund Flows
Monthly money in and out of Biotechnology UltraSector ProFund, from SEC Form N-PORT.
- 12-month net flow: −$16.9M
- 12-month gross sales (incl. reinvestments): $218.2M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $19.4M | $21.0M | −$1.7M |
| Jun 2026 | $18.7M | $16.7M | $2.0M |
| May 2026 | $3.7M | $84.2M | −$80.5M |
| Apr 2026 | $12.9M | $12.7M | $173K |
| Mar 2026 | $10.4M | $13.3M | −$2.9M |
| Feb 2026 | $9.9M | $12.6M | −$2.7M |
| Jan 2026 | $20.2M | $26.8M | −$6.6M |
| Dec 2025 | $84.3M | $11.0M | $73.3M |
| Nov 2025 | $17.5M | $11.4M | $6.1M |
| Oct 2025 | $13.0M | $11.4M | $1.6M |
| Sep 2025 | $4.2M | $8.1M | −$3.9M |
| Aug 2025 | $4.1M | $5.9M | −$1.8M |
BIPIX Assets Under Management
Net assets of Biotechnology UltraSector ProFund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $118.70M |
| 2026-04-30 | $182.58M |
| 2026-01-31 | $177.37M |
| 2025-10-31 | $87.62M |
| 2025-07-31 | $62.77M |
| 2025-04-30 | $66.23M |
| 2025-01-31 | $84.89M |
| 2024-10-31 | $100.49M |
| 2024-07-31 | $108.76M |
| 2024-04-30 | $94.51M |
| 2024-01-31 | $106.44M |
| 2023-10-31 | $77.10M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.